Experimental cell therapy studied for rare blood cancers, but trial stopped early
Disease control
Terminated
This study tested a treatment called brexucabtagene autoleucel, a type of cell therapy, in adults with rare B-cell blood cancers that had come back or stopped responding to standard treatments. The cancers included Waldenstrom macroglobulinemia, Richter transformation, Burkitt ly…
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC